Lung Cancer Prevalence after 4 years of screening in a COPD/Emphysema centered screening program
2019; Elsevier BV; Linguagem: Inglês
10.1183/13993003.congress-2019.pa3024
ISSN1872-8332
AutoresMaría De Los Ángeles Zambrano Chacón, Laura Ñúñez García, Carolina Gotera Rivera, María Teresa Pérez Warnisher, Rosario Melchor Íñiguez, Erwin Javier Pinillos Robles, Elena Cabezas Pastor, Abdulkader El Hachem Debek, Marcel Rodríguez Guzmán, Patricia Lazo Meneses, Javier Alfayate Sánchez, Nicolás González Mangado, Germán Peces-Barba Romero, Luis Seijó,
Tópico(s)Lung Cancer Diagnosis and Treatment
ResumoIntroduction: Lung cancer screening (LCS) with low-dose computed tomography (LDCT) reduces mortality from lung cancer in high risk individuals. Aim: The objective of this study was to identify the prevalence of LC in a population of high risk subjects meeting NLST criteria with COPD and or emphysema as an additional risk factor for LC. Material and Methods: Prospective cross-sectional analysis of the LCS program cohort. A total of 1005 patients were included, of which 949 have at least one baseline LDCT. Follow up adhered to the well established i-ELCAP protocol. Prevalence of lung cancer, histology, CT findings, lung function and epidemiologic variables were recorded. Results: The prevalence of LC was 2,31% (n=22). 13% had an extra-pulmonary synchronic cancer. The most frequent type of LC was adenocarcinoma (64%), followed by squamous cell carcinoma (23%). Most LCs were operable (64% in stages I and II). Surgery was the most frequent treatment in 64% of the patients. Median survival at 4 years was 94%. Pulmonary emphysema was present in 86% of patients with LC, and 80% were active smokers. COPD and emphysema coexisted in 73% of the patients with LC. Conclusion: A COPD/emphysema based strategy for the selection of LCS candidates is feasible. The prevalence of LC in our high risk cohort was 2.31%. 64% of patients were operable, and median survival at 4 years was 94%.
Referência(s)